SOTIO Reports First Patient Dosing of Nanrilkefusp Alfa in P-II Trial (AURELIO-05) for Colorectal Cancer
Shots:
- The first patient has been dosed in the P-II study (AURELIO-05) evaluating the efficacy and safety of nanrilkefusp alfa + cetuximab in ~52 patients with RAS wild-type colorectal cancer who are intolerant to prior treatment with irinotecan- and oxaliplatin-containing CT at ~20 sites across EU
- In previous studies, therapy showed promising signs of safety and efficacy as monotx. or in combination with pembrolizumab
- Strong preclinical in vivo efficacy of nanrilkefusp alfa in multiple tumor models have been shown with improved long-term survival and tumor regression along with a favorable toxicology profile. Nanrilkefusp alfa is an IL-15 superagonist that has been developed from the IL-15 technology platform
Ref: Globe Newswire | Image: Sotio
Related News:- Sotio Signs a Multiple Agreement with LegoChem Biosciences to Develop Novel Therapeutics for the Treatment of Solid Tumors
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
